0
     

Report Added
Report already added
Atrial Fibrillation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Atrial Fibrillation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 2, 3, 11, 4, 1, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Atrial Fibrillation - Overview
Atrial Fibrillation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Atrial Fibrillation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Atrial Fibrillation - Companies Involved in Therapeutics Development
AbbVie Inc
Acesion Pharma Aps
Aetas Pharma Co Ltd
AnaBios Corp
Anthos Therapeutics Inc
ARCA biopharma Inc
Armaron Bio Pty Ltd
Bayer AG
Bristol-Myers Squibb Co
Chaperone Pharma BV
Chong Kun Dang Pharmaceutical Corp
Correvio Pharma Corp
Daiichi Sankyo Co Ltd
Espero BioPharma Inc
FB HRS LLC
G3 Pharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
HUYA Bioscience International LLC
Hyloris Pharmaceuticals SA
InCarda Therapeutics Inc
Inomagen Therapeutics Inc
Merck & Co Inc
Merz Pharma GmbH & Co KgaA
Milestone Pharmaceuticals Inc
Nissan Chemical Corp
Novartis AG
Rithim Biologics Inc
The Geneva Biotech Center SA
Toa Eiyo Ltd
Verseon Corp
Vivasc Therapeutics Inc
Atrial Fibrillation - Drug Profiles
abelacimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
amiodarone - Drug Profile
Product Description
Mechanism Of Action
History of Events
AP-30663 - Drug Profile
Product Description
Mechanism Of Action
History of Events
asundexian - Drug Profile
Product Description
Mechanism Of Action
History of Events
bucindolol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
budiodarone - Drug Profile
Product Description
Mechanism Of Action
History of Events
CHAP-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CKD-825 - Drug Profile
Product Description
Mechanism Of Action
History of Events
danicamtiv - Drug Profile
Product Description
Mechanism Of Action
History of Events
dofetilide - Drug Profile
Product Description
Mechanism Of Action
edoxaban tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
etripamil - Drug Profile
Product Description
Mechanism Of Action
History of Events
FBHRS-001 - Drug Profile
Product Description
Mechanism Of Action
flecainide acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
GBCA-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
gemibotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Post-Operative Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
HBI-3000 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HIP-2001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HSY-244 - Drug Profile
Product Description
Mechanism Of Action
History of Events
incobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
History of Events
M-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MK-1832 - Drug Profile
Product Description
Mechanism Of Action
NIP-151 - Drug Profile
Product Description
Mechanism Of Action
NP-202 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NTC-801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System Disorders - Drug Profile
Product Description
Mechanism Of Action
TY-55348 - Drug Profile
Product Description
Mechanism Of Action
TY-55458 - Drug Profile
Product Description
Mechanism Of Action
VE-1902 - Drug Profile
Product Description
Mechanism Of Action
History of Events
vernakalant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Atrial Fibrillation - Dormant Projects
Atrial Fibrillation - Discontinued Products
Atrial Fibrillation - Product Development Milestones
Featured News & Press Releases
Dec 07, 2021: Atrial Fibrillation clinical trial with novel dual activity factor XI agent completes enrollment
Nov 15, 2021: Milestone Pharmaceuticals announces presentation of heart rate analysis of NODE-301 trial of Etripamil in Patients with PSVT
Nov 02, 2021: HUYABIO International announces initiation of phase 2 atrial fibrillation trial
Aug 30, 2021: ENVISAGE-TAVI AF data published in The NEJM demonstrates edoxaban’s noninferiority to VKAs in High-risk AF patients following successful heart valve procedure
Aug 28, 2021: New data support the use of LIXIANA (edoxaban) in complex patient populations with atrial fibrillation (AF)
Aug 28, 2021: Edoxaban may be effective treatment for atrial fibrillation after transcatheter aortic valve replacement
Jun 23, 2021: InCarda Therapeutics announces positive end-of-phase 2 meeting with FDA for InRhythm for Treatment of atrial fibrillation
Jun 09, 2021: InCarda Therapeutics provides corporate update highlighting new phase 2 data for InRhythm program, plans for pivotal phase 3 study and expansion of senior management team
Apr 26, 2021: New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA (edoxaban) in people with atrial fibrillation
Apr 21, 2021: Rhythm Therapeutics, awarded $3.67 Million NIH SBIR fast track grant to develop gene therapy for atrial fibrillation
Mar 29, 2021: Milestone Pharmaceuticals announces first patient enrolled in the ReVeRA study, its phase 2 trial of Etripamil in atrial fibrillation and rapid ventricular rate
Jan 19, 2021: InCarda Therapeutics announces enrollment of first U.S. patient in phase 2 INSTANT trial of InRhythm for treatment of atrial fibrillation
Nov 13, 2020: InCarda Therapeutics presents positive new data from phase 2 study of InRhythm in patients with paroxysmal atrial fibrillation at American Heart Association Scientific Sessions 2020
Sep 11, 2020: Daiichi Sankyo submits Supplemental Application in Japan for approval of partial changes in usage or dosage for Anticoagulant Edoxaban
Aug 31, 2020: New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and ageing AF patients on LIXIANA (edoxaban) during routine clinical care
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Atrial Fibrillation, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Atrial Fibrillation - Pipeline by AbbVie Inc, 2022
Atrial Fibrillation - Pipeline by Acesion Pharma Aps, 2022
Atrial Fibrillation - Pipeline by Aetas Pharma Co Ltd, 2022
Atrial Fibrillation - Pipeline by AnaBios Corp, 2022
Atrial Fibrillation - Pipeline by Anthos Therapeutics Inc, 2022
Atrial Fibrillation - Pipeline by ARCA biopharma Inc, 2022
Atrial Fibrillation - Pipeline by Armaron Bio Pty Ltd, 2022
Atrial Fibrillation - Pipeline by Bayer AG, 2022
Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Co, 2022
Atrial Fibrillation - Pipeline by Chaperone Pharma BV, 2022
Atrial Fibrillation - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
Atrial Fibrillation - Pipeline by Correvio Pharma Corp, 2022
Atrial Fibrillation - Pipeline by Daiichi Sankyo Co Ltd, 2022
Atrial Fibrillation - Pipeline by Espero BioPharma Inc, 2022
Atrial Fibrillation - Pipeline by FB HRS LLC, 2022
Atrial Fibrillation - Pipeline by G3 Pharmaceuticals Inc, 2022
Atrial Fibrillation - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Atrial Fibrillation - Pipeline by HUYA Bioscience International LLC, 2022
Atrial Fibrillation - Pipeline by Hyloris Pharmaceuticals SA, 2022
Atrial Fibrillation - Pipeline by InCarda Therapeutics Inc, 2022
Atrial Fibrillation - Pipeline by Inomagen Therapeutics Inc, 2022
Atrial Fibrillation - Pipeline by Merck & Co Inc, 2022
Atrial Fibrillation - Pipeline by Merz Pharma GmbH & Co KgaA, 2022
Atrial Fibrillation - Pipeline by Milestone Pharmaceuticals Inc, 2022
Atrial Fibrillation - Pipeline by Nissan Chemical Corp, 2022
Atrial Fibrillation - Pipeline by Novartis AG, 2022
Atrial Fibrillation - Pipeline by Rithim Biologics Inc, 2022
Atrial Fibrillation - Pipeline by The Geneva Biotech Center SA, 2022
Atrial Fibrillation - Pipeline by Toa Eiyo Ltd, 2022
Atrial Fibrillation - Pipeline by Verseon Corp, 2022
Atrial Fibrillation - Pipeline by Vivasc Therapeutics Inc, 2022
Atrial Fibrillation - Dormant Projects, 2022
Atrial Fibrillation - Dormant Projects, 2022 (Contd..1)
Atrial Fibrillation - Dormant Projects, 2022 (Contd..2)
Atrial Fibrillation - Discontinued Products, 2022
Atrial Fibrillation - Discontinued Products, 2022 (Contd..1)

List of Figures
Number of Products under Development for Atrial Fibrillation, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Atrial Fibrillation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW